|
Capricor is adamant its Phase III study showed effectiveness, though panel members called data “fragile”.
|
 |
|
GSK will reallocate a large portion of capital saved from the £1.9bn cost-cutting scheme towards late-stage pipeline acceleration, primarily focused on oncology.
|
|
|
If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.
|
|
|
Regenerative medicine offers an innovative approach to treating different indications by restoring damaged or diseased cells and tissues.
|
|
|
The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.
|
|
|
Dimerix adds DMX-652, a Phase II-ready AKI asset, strengthening its kidney disease pipeline beyond FSGS.
|
|
